Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Master's Award: Canada Graduate Research Scholarships - Master's program

University of British Columbia

$27,000.00

Early on-treatment circulating tumour DNA fraction change as a predictor of Lutetium-177-PSMA-617 therapy response in metastatic castration-resistant prostate cancer

EF 2025-26

Résumé
Patients with prostate cancer that has spread to other organs undergo treatment with the goal of shrinking their cancer to extend life. Lutetium-177-PSMA-617 (LuPSMA) is a new class of therapy for this disease that targets tumours directly with radiation. Even though clinical trials have found that LuPSMA broadly improves outcomes, not all patients benefit equally. Detecting whether treatment is ineffective early on is crucial to limit patient exposure to side effects and high costs. Unfortunately, current tests that monitor response do not reliably predict outcomes early; an alternative method is needed. Tumours shed genetic material, called circulating tumour DNA (ctDNA), into the blood of patients with cancer. The amount of ctDNA in the blood can tell us how aggressive a cancer is at a given timepoint. Research suggests that measuring ctDNA levels in the early stages of treatment can tell us if a cancer is shrinking in response to therapy. Here, I will study pre- and on-treatment blood samples from patients who received LuPSMA therapy, using computational methods to determine the exact change in ctDNA levels over 12 weeks of LuPSMA treatment that signals a true treatment response. Then, I will compare my defined ctDNA change thresholds to other standard measures of treatment response to see if ctDNA provides more accurate predictions. Ultimately, my research will improve response monitoring for patients being treated with LuPSMA. Identifying treatment failure early will allow patients to switch to more effective options in a timely manner. Furthermore, it will minimize treatment-related toxicity and costs. Finally, this minimally-invasive response monitoring can be performed out-of-hospital, making personalized cancer care more accessible.
Programme
Master's Award: Canada Graduate Research Scholarships - Master's program
Emplacement
British Columbia, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
573316
Name
Wang Catherine
Region
British Columbia
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Early on-treatment circulating tumour DNA fraction change as a predictor of Lutetium-177-PSMA-617 therapy response in metastatic castration-resistant prostate cancer
Programtype2
Studentship Programs
Orgnameinp2
University of British Columbia
Cihramount2
$27,000
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Research Scholarships - Master's program
Keyworddelim
Bioinformatics; Biomarkers; Cell-Free Dna; Circulating Tumour Dna; Metastatic Prostate Cancer; Precision Oncology; Prostate Cancer; Radioligand Therapy; Response Monitoring; Targeted Therapy
Abstract
Patients with prostate cancer that has spread to other organs undergo treatment with the goal of shrinking their cancer to extend life. Lutetium-177-PSMA-617 (LuPSMA) is a new class of therapy for this disease that targets tumours directly with radiation. Even though clinical trials have found that LuPSMA broadly improves outcomes, not all patients benefit equally. Detecting whether treatment is ineffective early on is crucial to limit patient exposure to side effects and high costs. Unfortunately, current tests that monitor response do not reliably predict outcomes early; an alternative method is needed. Tumours shed genetic material, called circulating tumour DNA (ctDNA), into the blood of patients with cancer. The amount of ctDNA in the blood can tell us how aggressive a cancer is at a given timepoint. Research suggests that measuring ctDNA levels in the early stages of treatment can tell us if a cancer is shrinking in response to therapy. Here, I will study pre- and on-treatment blood samples from patients who received LuPSMA therapy, using computational methods to determine the exact change in ctDNA levels over 12 weeks of LuPSMA treatment that signals a true treatment response. Then, I will compare my defined ctDNA change thresholds to other standard measures of treatment response to see if ctDNA provides more accurate predictions. Ultimately, my research will improve response monitoring for patients being treated with LuPSMA. Identifying treatment failure early will allow patients to switch to more effective options in a timely manner. Furthermore, it will minimize treatment-related toxicity and costs. Finally, this minimally-invasive response monitoring can be performed out-of-hospital, making personalized cancer care more accessible.
Competitiondate
202512
Approvedterm2
1 yr 0 mth
Pinamesdelim
Wang, Catherine
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $27,000~ $0~